Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Cardiff Oncology fourth quarter 2024 financial results and business update conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone, and you will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to turn the conference call over to Kiki Patel of Gilman Group. Oh, sorry, Gilmartin Group, my reading. Please go ahead. Thank you, operator. Joining us on the call today, from Cardiff Oncology, our Chief Executive Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine. During the conference call, management will make forward-looking statements, including without limitation, statements related to guidance, results, and timing of data readouts for OnVansertib clinical trials. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the company describes in the section titled Risk Factors in its annual report on Form 10-K filed with the SEC for the year ended December 31, 2024. Cardiff Oncology undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. With that, I turn the call over to Chief Executive Officer Mark Erlander. Mark? Well, thank you, Kiki, a...